Načítá se...
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy
BRAF inhibitor treatment (BRAFi) enhances anti-tumor immunity, but is associated with increased intra-tumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function, however recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4506225/ https://ncbi.nlm.nih.gov/pubmed/26025561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0363 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|